The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
The Ras-Raf-MEK-ERK Pathway in the Treatment of Cancer
Abstract
The mitogen activated protein kinases (MAPKs) are conserved proteins that regulate cell growth, division and death. Although activated in the cytosol, the MAPKs translocate to the nucleus upon activation and phosphorylate a large number of nuclear proteins. Investigating how Ras transmits extracellular growth signals, the MAPK pathway has emerged as the crucial route between membrane-bound Ras and the nucleus. The MAPK pathway represents a cascade of phosphorylation events including three pivotal kinases, namely Raf, MEK (MAP kinase kinase), and ERK (MAP kinase). These kinases present new opportunities for the development of novel anti-cancer drugs designed to be target-specific and probably less toxic than conventional chemotherapeutic agents. A number of drugs inhibiting Ras, Raf or MEK are currently under clinical investigation. This review addresses the rationale for targeting the MAP kinase pathway and the current status of various pharmacological approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Mitogen-activated protein kinase pathways
Robinson, M. J., & Cobb, M. H. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80061-0 · Cited by 2,474
Cowley, S. (1994) · Cell · doi:10.1016/0092-8674(94)90133-3 · Cited by 1,966
Signal Transduction through MAP Kinase Cascades
(1998) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60765-4 · Cited by 1,759
Mitogen-Activated Protein Kinases: Specific Messages from Ubiquitous Messengers
Schaeffer, H. J., & Weber, M. J. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.4.2435 · Cited by 1,600
Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions
Kölch, W. (2000) · Biochemical Journal · doi:10.1042/0264-6021:3510289 · Cited by 1,441
Transformation of Mammalian Cells by Constitutively Active MAP Kinase Kinase
Mansour, S. J., Matten, W. T., Hermann, A. S., Candia, J. M., Rong, S., Fukasawa, K., Vande Woude, G. F., & Ahn, N. G. (1994) · Science · doi:10.1126/science.8052857 · Cited by 1,353
Protein kinase Cα activates RAF-1 by direct phosphorylation
Kolch, W., Heidecker, G., Kochs, G., Hummel, R., Vahidi, H., Mischak, H., Finkenzeller, G., Marmé, D., & Rapp, U. R. (1993) · Nature · doi:10.1038/364249a0 · Cited by 1,277
FUNCTION AND REGULATION OF RAS
Lowy, D. R., & Willumsen, B. M. (1993) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.62.070193.004223 · Cited by 1,186
Anderson, N. G., Maller, J. L., Tonks, N. K., & Sturgill, T. W. (1990) · Nature · doi:10.1038/343651a0 · Cited by 1,063
Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
Sebolt-Leopold, J. S., Dudley, D. T., Herrera, R., Becelaere, K. V., Wiland, A., Gowan, R. C., Tecle, H., Barrett, S. D., Bridges, A., Przybranowski, S., et al. (1999) · Nature Medicine · doi:10.1038/10533 · Cited by 970
Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2
Waskiewicz, A. J. (1997) · The EMBO Journal · doi:10.1093/emboj/16.8.1909 · Cited by 947
The Primary Structure of MEK, a Protein Kinase that Phosphorylates the ERK Gene Product
Crews, C. M., Alessandrini, A., & Erikson, R. L. (1992) · Science · doi:10.1126/science.1411546 · Cited by 913
Cobb, M. H. (1999) · Progress in Biophysics and Molecular Biology · doi:10.1016/s0079-6107(98)00056-x · Cited by 875
Bcl-2 Targets the Protein Kinase Raf-1 to Mitochondria
Wang, H.-G., Rapp, U. R., & Reed, J. C. (1996) · Cell · doi:10.1016/s0092-8674(00)81383-5 · Cited by 766
Activation of Mitogen-Activated Protein Kinase Kinase by v-Raf in NIH 3T3 Cells and in Vitro
Dent, P., Haser, W., Haystead, T. A. J., Vincent, L. A., Roberts, T. M., & Sturgill, T. W. (1992) · Science · doi:10.1126/science.1326789 · Cited by 668
Fukunaga, R. (1997) · The EMBO Journal · doi:10.1093/emboj/16.8.1921 · Cited by 663
The complexity of Raf-1 regulation
Morrison, D. K., & Cutler, R. E. (1997) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(97)80060-9 · Cited by 635
Ras Protein Farnesyltransferase: A Strategic Target for Anticancer Therapeutic Development
Rowinsky, E. K., Windle, J. J., & Von Hoff, D. D. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3631 · Cited by 537
Karp, J. E., Lancet, J. E., Kaufmann, S. H., End, D. W., Wright, J. J., Bol, K., Horak, I., Tidwell, M. L., Liesveld, J., Kottke, T. J., et al. (2001) · Blood · doi:10.1182/blood.v97.11.3361 · Cited by 443
Distinct requirements for Ras oncogenesis in human versus mouse cells
Hamad, N. M., Elconin, J. H., Karnoub, A. E., Bai, W., Rich, J. N., Abraham, R. T., Der, C. J., & Counter, C. M. (2002) · Genes & Development · doi:10.1101/gad.993902 · Cited by 431
Transcriptional regulation by MAP kinases
Davis, R. J. (1995) · Molecular Reproduction and Development · doi:10.1002/mrd.1080420414 · Cited by 429
McCormick, F. (1993) · Nature · doi:10.1038/363015a0 · Cited by 408
Dalby, K. N., Morrice, N., Caudwell, F. B., Avruch, J., & Cohen, P. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.3.1496 · Cited by 372
Seger, R., Ahn, N. G., Posada, J., Munar, E. S., Jensen, A. M., Cooper, J. A., Cobb, M. H., & Krebs, E. G. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)49722-6 · Cited by 364
Signaling by dual specificity kinases
Dhanasekaran, N., & Reddy, E. P. (1998) · Oncogene · doi:10.1038/sj.onc.1202251 · Cited by 301
Paradoxical activation of Raf by a novel Raf inhibitor
Hall-Jackson, C. A., Eyers, P. A., Cohen, P., Goedert, M., Tom Boyle, F., Hewitt, N., Plant, H., & Hedge, P. (1999) · Chemistry & Biology · doi:10.1016/s1074-5521(99)80088-x · Cited by 265
Zujewski, J., Horak, I. D., Bol, C. J., Woestenborghs, R., Bowden, C., End, D. W., Piotrovsky, V. K., Chiao, J., Belly, R. T., Todd, A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.4.927 · Cited by 264
Isotype-Specific Functions of Raf Kinases
Hagemann, C., & Rapp, U. R. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4689 · Cited by 261
Analysis of the transcriptional program induced by Raf in epithelial cells
Schulze, A., Lehmann, K., Jefferies, H. B. J., McMahon, M., & Downward, J. (2001) · Genes & Development · doi:10.1101/gad.191101 · Cited by 259
Adjei, A. A., Erlichman, C., Davis, J. N., Cutler, D. L., Sloan, J. A., Marks, R. S., Hanson, L. J., Svingen, P. A., Atherton, P. J., Bishop, W. R., et al. (2000) · PubMed · Cited by 242
Human breast carcinoma desmoplasia is PDGF initiated
Shao, Z.-M., Nguyen, M., & Barsky, S. H. (2000) · Oncogene · doi:10.1038/sj.onc.1203785 · Cited by 221
Adjei, A. A., Mauer, A., Bruzek, L., Marks, R. S., Hillman, S., Geyer, S., Hanson, L. J., Wright, J. J., Erlichman, C., Kaufmann, S. H., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.075 · Cited by 219
KSR is a scaffold required for activation of the ERK/MAPK module
Roy, F., Laberge, G., Douziech, M., Ferland-McCollough, D., & Therrien, M. (2002) · Genes & Development · doi:10.1101/gad.962902 · Cited by 217
Aberrant function of the Ras signal transduction pathway in human breast cancer
Clark, G. J., & Der, C. J. (1995) · Breast Cancer Research and Treatment · doi:10.1007/bf00694753 · Cited by 213
Lackner, M. R., Kornfeld, K., Miller, L. M., Horvitz, H. R., & Kim, S. K. (1994) · Genes & Development · doi:10.1101/gad.8.2.160 · Cited by 210
Ras activation in human breast cancer
von Lintig, F. C., Dreilinger, A. D., Varki, N. M., Wallace, A. M., Casteel, D. E., & Boss, G. R. (2000) · Breast Cancer Research and Treatment · doi:10.1023/a:1006491619920 · Cited by 184
Chow, S., Patel, H., & Hedley, D. W. (2001) · Cytometry · doi:10.1002/cyto.1067 · Cited by 181
Cohen, S. J., Ho, L., Ranganathan, S., Abbruzzese, J. L., Alpaugh, R. K., Beard, M., Lewis, N. L., McLaughlin, S., Rogatko, A., Perez-Ruixo, J. J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.040 · Cited by 174
The 3Rs of life: Ras, Raf and growth regulation
Moodie, S. A., & Wolfman, A. (1994) · Trends in Genetics · doi:10.1016/0168-9525(94)90147-3 · Cited by 163
Regulation of cell proliferation by G proteins
Dhanasekaran, N., Tsim, S.-T., Dermott, J. M., et al. (1998) · Oncogene · doi:10.1038/sj.onc.1202242 · Cited by 151
Monia, B. P., Sasmor, H. M., Johnston, J. F., Freier, S. M., Lesnik, E. A., Muller, M., Geiger, T. M., Altmann, K., Moser, H. E., & Fabbro, D. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.26.15481 · Cited by 136
Suzuki, T., Kawamura-Tsuzuku, J., Ajima, R., Nakamura, T., Yoshida, Y., & Yamamoto, T. S. (2002) · Genes & Development · doi:10.1101/gad.962802 · Cited by 136
Stevenson, J. P., Yao, K.-S., Gallagher, M., Friedland, D. P., Mitchell, E. P., Cassella, A., Monia, B. P., Kwoh, T. J., Yu, R. Z., Holmlund, J., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2227 · Cited by 129
Dual phosphorylation and autophosphorylation in mitogen-activated protein (MAP) kinase activation
Her, J. H., Lakhani, S., Zu, K., Vilà, J., Dent, P., Sturgill, T. W., & Weber, M. J. (1993) · Biochemical Journal · doi:10.1042/bj2960025 · Cited by 126
Cunningham, C. C., Holmlund, J., Schiller, J. H., Geary, R. S., Kwoh, T. J., Dorr, A., & Nemunaitis, J. J. (2000) · PubMed · Cited by 126
Eskens, F. A. L. M., Awada, A. H., Cutler, D. L., de Jonge, M. J. A., Luyten, G. P. M., Faber, M. N., Statkevich, P., Sparreboom, A., Verweij, J., Hanauske, A., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.1167 · Cited by 125
Wu, Y. L., Han, M., & Guan, K. (1995) · Genes & Development · doi:10.1101/gad.9.6.742 · Cited by 120
Comparison of potential markers of farnesyltransferase inhibition.
Adjei, A. A., Davis, J. N., Erlichman, C., Svingen, P. A., & Kaufmann, S. H. (2000) · PubMed · Cited by 119
Tolcher, A. W., Reyno, L. M., Venner, P. M., Ernst, S., Moore, M. J., Geary, R. S., Chi, K., Hall, S. R. R., Walsh, W., Dorr, A., et al. (2002) · PubMed · Cited by 119
junB promoter regulation: Ras mediated transactivation by c-Ets-1 and c-Ets-2.
Coffer, P. J., de Jonge, M., Mettouchi, A., Binétruy, B., Ghysdael, J., & Kruijer, W. (1994) · PubMed · Cited by 104
Strumberg, D., Voliotis, D., Moeller, J.-G., Hilger, R. A., Richly, H., Kredtke, S., Beling, C., Scheulen, M. E., & Seeber, S. (2002) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cpp40580 · Cited by 104
Self-citationCripps, M. C., Figueredo, A. T., Oza, A. M., Taylor, M. J., Fields, A. L. A., Holmlund, J. T., McIntosh, L., Geary, R. S., & Eisenhauer, E. A. (2002) · PubMed · Cited by 96
Clark, G. J., Kinch, M. S., Gilmer, T. M., Burridge, K., & Der, C. J. (1996) · PubMed · Cited by 88
Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells
Tamanoi, F., Gau, C. ‐., Jiang, C., Edamatsu, H., & Kato‐Stankiewicz, J. (2001) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000802 · Cited by 84
Farnesyltransferase inhibitors: mechanism and applications
Rane, N. S., & Prendergast, G. C. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.12.2105 · Cited by 78
Oncogene activation: c-raf-1 gene mutations in experimental and naturally occurring tumors
Storm, S. M., & Rapp, U. R. (1993) · Toxicology Letters · doi:10.1016/0378-4274(93)90056-4 · Cited by 53
Henry, S. P., Monteith, D. K. B., Bennett, F., et al. (1997) · PubMed · Cited by 48
Ogata, H., Sato, H., Takatsuka, J., & Luca, L. M. D. (2001) · Cancer Letters · doi:10.1016/s0304-3835(01)00648-6 · Cited by 43
Cited by
Mitogen-activated protein kinases in apoptosis regulation
Wada, T., & Penninger, J. M. (2004) · Oncogene · doi:10.1038/sj.onc.1207556 · Cited by 1,432
BRAF mutation in thyroid cancer
Xing, M. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.0978 · Cited by 1,300
Ratain, M. J., Eisen, T., Stadler, W. M., Flaherty, K. T., Kaye, S. B., Rosner, G. L., Gore, M., Desai, A. A., Patnaik, A., Xiong, H. Q., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6723 · Cited by 1,032
BRAF Mutation Predicts a Poorer Clinical Prognosis for Papillary Thyroid Cancer
Xing, M., Westra, W. H., Tufano, R. P., Cohen, Y., Rosenbaum, E., Rhoden, K. J., Carson, K. A., Vasko, V., Larin, A., Tallini, G., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0987 · Cited by 993
Strumberg, D., Richly, H., Hilger, R. A., Schleucher, N., Korfee, S., Tewes, M., Faghih, M., Brendel, E., Voliotis, D., Haase, C. G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.124 · Cited by 872
Self-citation
Metadata
- Authors
- Hilger, R. A., Scheulen, M. E., & Strumberg, D.
- Venue
- Oncology Research and Treatment
- Publisher
- S. Karger AG
- Published
- 2002
- Volume
- 25
- Issue
- 6
- Pages
- 511-518
- ISSN
- 2296-5262 (ISSN-L)
- 2296-5270
- OpenAlex
- W2047198790
- Cited by
- 265
- References
- 60
- FWCI
- 5.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.